Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease

E. E. Guffanti, P. Scarpazza, D. Colombo, S. Canali, D. Ratti, G. Scarpazza, E. Marchi

Research output: Contribution to journalArticle

Abstract

The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.

Original languageEnglish
Pages (from-to)185-196
Number of pages12
JournalAdvances in Therapy
Volume12
Issue number3
Publication statusPublished - 1995

Keywords

  • chronic obstructive pulmonary disease
  • moguisteine
  • pharmacokinetics
  • theophylline

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this